Beth Israel Medical Center

IceCure Medical Sees Sales Surge and Awaits FDA Decision on ProSense for Breast Cancer

4 months ago

• IceCure Medical reported a 42% increase in North American sales of its ProSense cryoablation system in 2024, signaling growing adoption for breast tumor treatment. • The company anticipates an FDA decision on ProSense for early-stage breast cancer in Q1 2025, following positive advisory panel feedback based on the ICE3 study. • ICE3 study results showed a 96.3% recurrence-free rate and 100% patient/physician satisfaction, aligning with lumpectomy outcomes for early-stage breast cancer. • Interim results from the ICESECRET kidney cancer study demonstrated an 88.7% recurrence-free rate, highlighting ProSense's potential in treating kidney cancer.

FDA Approves Bimzelx (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa

6 months ago

• The FDA has approved Bimzelx (bimekizumab-bkzx) for treating moderate-to-severe hidradenitis suppurativa (HS) in adults, offering a new treatment option. • Bimzelx is the first treatment of its kind, selectively inhibiting both IL-17A and IL-17F, providing a novel approach to managing this inflammatory skin condition. • Clinical trials demonstrated that Bimzelx achieved significant and sustained clinical responses in patients with HS over a 48-week period. • Data presented at ACR Convergence 2024 highlighted Bimzelx's sustained efficacy in treating psoriatic arthritis and axial spondyloarthritis over two years.